IDiyas

For the Inventor, By the Inventor

Boulder, CO, United States of America

Elizabeth A McFaddin

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 13.9

ph-index = 4

Forward Citations = 46(Granted Patents)


Location History:

  • Nederland, CO (US) (2023)
  • Boulder, CO (US) (2018 - 2024)

Company Filing History:

goldMedal13 out of 329 
 
Array Biopharma Inc.
 patents
silverMedal3 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 2018-2024

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),
2. 11697647 - RET kinase inhibitors (2023-07-11),
3. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),
4. 11613533 - Compounds useful for inhibiting RET kinase (2023-03-28),
5. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),
6. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),
7. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),
8. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),
9. 10584124 - Crystalline forms (2020-03-10),
10. 10555944 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2020-02-11),
11. 10441581 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-10-15),
12. 10172851 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),
13. 10172845 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),
14. 10144734 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2018-12-04),
15. 10137124 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2018-11-27),

Title: The Innovative Contributions of Elizabeth A McFaddin

Introduction

Elizabeth A McFaddin is a prominent inventor based in Boulder, Colorado, known for her significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, she has made strides in developing compounds that target critical health issues.

Latest Patents

Among her latest patents are the "Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors." These compounds are designed to inhibit RET kinase, which is crucial in treating and preventing diseases associated with RET, including various cancers. Another notable patent involves formulations containing these compounds, which are essential for developing effective treatments for RET-associated cancers.

Career Highlights

Throughout her career, Elizabeth has worked with leading companies in the pharmaceutical industry, including Array Biopharma Inc. and Eli Lilly and Company. Her work has focused on innovative solutions that address complex medical challenges, showcasing her expertise and dedication to advancing healthcare.

Collaborations

Elizabeth has collaborated with talented individuals in her field, including Gabrielle R Kolakowski and Julia Haas. These partnerships have contributed to her success and the development of groundbreaking therapies.

Conclusion

Elizabeth A McFaddin's innovative work in developing RET kinase inhibitors highlights her significant impact on the pharmaceutical industry. Her contributions continue to pave the way for advancements in treating critical health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…